65,437 trials
Parkinson Disease
Primary: Maximum Observed Plasma Concentration (Cmax) — 0.281; 2.29; 2.74 (ng/mL)/(mg)
Arthritis, Rheumatoid
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 14; 7; 1 Participants
Metastatic Breast Cancer
Primary: Percentage of Participants With Severe Diarrhea (≥ Grade 3) — 4.2; 0; 0 percentage of participants
Multiple Myeloma
Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)…
Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose (MTD) or Biologically Active Dose of Cirmtuzumab — 20 mg/kg
Gastrointestinal Microbiome
Primary: Composition of Stool Micro Biome Diversity and Phylogenetic Distribution at 0 Days, 8 Days and 28 Days — 0.697; 0.722; 0.735; 0.146 ratio
Agitation
Primary: Average Daily Dexmedetomidine mcg/kg/Day — 11.08; 17.42 mcg/kg/day
Malignant Pleural Effusion
Primary: The Proportion of Subjects Achieving Pleurodesis Without Recurrence. — 17; 12 Participants
Cigarette Smoking
Primary: BOLD Activation to Smoking Cues - Amygdala — 0.002471; 0.077325; 0.009450; 0.090345 Percent Signal Change — p=.019
Inflammation · Platelet Dysfunction
Primary: Change in Platelet Count — -221; -242 Count of platelets — p=0.55
Adolescents · 18 and Under When Child Was Born for Mothers · 25 and Under When Child Was Born for Fathers
Primary: Rapid Repeat Pregnancy — 8; 16 Participants — p=.037
Lymphoma
Primary: Percentage of Participants With Administration-Associated Reactions (AAR) — 4.2; 8.1; 6.3; 0 Percentage of Participants
Multiple Sclerosis
Primary: Total Steps Taken Over Course of the Study — 296,147 steps over 4 weeks
Hemophilia A
Primary: Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay — 31.11 percentage of participants
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants